Featured Content

Winston Wong, PharmD
President, W-Squared Group

70-Gene Signature Not Cost-Effective in Breast Cancer

(Betty Hardwick Center/HealthDay News) Oct 17, 2014 — For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published online Oct. 6 in the Journal of Clinical Oncology.

Commentary: It would be interesting to see their analysis of OncoTypeDx in the same study setting. I know costs are very different...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

How Medicare ‘Self-Referral’ Thrives on Loophole

(Wall Street Journal) Oct 22, 2014 - In a letter to a friend, the manager of a Florida urology practice worried in 2010 that her company would attract federal scrutiny for its frequent use of an expensive bladder-cancer test.
read article (paid subscription required) »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



70-Gene Signature Not Cost-Effective in Breast Cancer (Betty Hardwick Center/HealthDay News)

It would be interesting to see their analysis of OncoTypeDx in the same study setting. I know costs are very different...posted by: Winston Wong, PharmD

European Commission Approves IMBRUVICA(TM) in Two Forms of Blood Cancer (Johnson & Johnson)

The clinicals for Imbruvica are strong. The safety profile is clean. We actually have an a therapeutic advancement...posted by: Winston Wong, PharmD

Maine Hospitals See Price Increase For Specialty Cancer Drugs (Maine Public Broadcasting [Bangor, ME])

Not only a headache for Hospitals, but also a headache for payers. Limited distribution has been in place for...posted by: Winston Wong, PharmD

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma (Yahoo! Finance)

Two drugs which are very effective in their own right. Combined, project the results, and then the demand, and...posted by: Winston Wong, PharmD

ASCO Endorses CAP/IASLC/AMP Guideline on EGFR and ALK Molecular Testing for Patients with Lung Cancer (ASCO)

While I am glad to see ASCO endorsing such testing, such testing, from the eyes of the payer, is accepted as standard...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


Bayer Biopharmaceuticals, Inc. has posted 20 new jobs.


Ipsen Biopharmaceuticals, Inc. has posted over 50 new jobs.


Novocure has posted 4 jobs.


View OBR Job Board>>




The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
CPXX +32.54%
ZIOP +9.50%
EPZM +9.20%
FATE -7.61%
CERU -3.69%
CRIS -3.65%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: H2 2014
Company: Amgen
Product: Trebananib

Date: September / October 2014
Company: Seattle Genetics / Takeda
Product: Adcetris® (brentuximab vedotin)

Date: Q4 2014
Company: Bristol-Myers Squibb / Ono Pharmaceutical Co.
Product: Opdivo® (nivolumab)

See All OBR Radar items»